Serum testosterone levels decline significantly with aging and this has been associated with reduced sexual function. We have conducted a double-blind, randomized, placebo-controlled trial to investigate the effect of testosterone supplementation on sexual function in 237 elderly men with a testosterone level o13.7 nmol l
Introduction
Many older men remain sexually active, but activity declines with age from 83.7% sexually active among men between 57 and 64 years of age, to 67% among men between 65 and 74 years of age and to 38.5% among men between 75 and 85 years of age. 1 According to a recent survey, half of the men who are sexually active report at least one bothersome sexual problem, of which the most common is erectile dysfunctions (37%). Other frequent sexual problems are lack of interest in sex (28%), inability to climax (20%) and climaxing too quickly (28%). 1 Impairment of sexual function has a major impact on the quality of life. 2 In aging men, sexual problems are believed to be related partly to hormonal status. Up to 35% of men with erectile dysfunction may have hypogonadism. 3, 4 Serum testosterone levels decline gradually with aging. 5 This decline coincides with increasing signs and symptoms of aging, including tiredness and lack of energy, diminished cognition, reduced muscle mass and strength, reduced bone density, depression and diminished well-being. However, the association between sexual functioning (diminished libido, erectile dysfunction) and testosterone levels is not consistent across studies. Although some investigators have reported a significant relation between testosterone levels and sexual function, 6, 7 others have found no association, 8, 9 possibly because of the relative effect of other chronic conditions common in elderly men, notably diabetes mellitus, depression and cardiovascular diseases, which may also affect sexual function.
Clinical trials examining the effect of testosterone supplementation on sexual function in aging men have produced conflicting findings. 10, 11 These divergent findings likely reflect differences in study design. In particular, most of the studies were probably too small in size and duration. Additional data are needed to determine whether older men receiving testosterone supplementation experience benefits on sexual functioning.
We conducted a randomized, double-blind placebo-controlled study to assess the effect of testosterone supplementation on sexual functioning in aging men with moderately low testosterone levels for a period of 6 months.
Materials and methods
This study had a randomized, double-blind, placebo-controlled design. Details of the study design, recruitment and procedures have been published earlier. 12 The Institutional Review Board of the University Medical Centre Utrecht approved the study protocol and all participants provided written informed consent. This study is a secondary analysis of a larger study published earlier. 13 
Participants
Participants were recruited by directly mailing to 8020 randomly selected men between 60 and 80 years of age whose addresses were obtained from the municipal register of the city of Utrecht (The Netherlands). Inclusion criteria included a testosterone level below the 50th percentile of the study-populationbased testosterone distribution and an age between 60 and 80 years. The 50th percentile cutoff level of testosterone was determined to be 13.7 nmol l À1 after screening of 50 candidates. This was similar to the 50th percentile of the testosterone level at the end of the study (13.8 nmol l
À1
). Exclusion criteria included myocardial infarction or cerebrovascular accident within the past 6 months, heart failure unless medically treated and not symptomatic, malignancy within the past 5 years except for non-melanoma skin cancer, any hormone-dependent tumor in the history of the participant, serious liver or renal diseases (more than three times the upper limit of reference value), hematological abnormalities (hemoglobin p7.0 mmol l À1 , hematocrit X0.50), epilepsy or the use of anti-epileptic medication, migraine more than once a month, diabetes mellitus, a fasting glucose level X6.9 mmol l À1 , corticosteroid use (X7.5 mg orally once a day within the past 6 months, with the exception of short bouts of prednisone for the period of 7 days, or inhalation of X800 mg once a day during the past 6 months), use of testosterone esters and alike substances within the past 60 days, prostate hypertrophy in medical history and an elevated PSA level (age 60-69 years X4.5 mg l
; 70 years and above X6.5 mg l
). Following an initial telephone contact, 684 men were screened with medical history, laboratory testing and digital rectal examination. Finally, 237 men were eligible for entry into the study and agreed to participate. Data collection took place between January 2004 and October 2004, and of the 237 men enrolled, 120 were assigned to testosterone and 117 to placebo. The flow of study subjects participants recruitment and enrollment is shown in Figure 1 .
Intervention
After entry into the study, the subjects were randomly assigned to treatment with either two capsules of 40 mg testosterone undecanoate (Andriol Testocaps, N.V. Organon, Oss, The Netherlands) twice a day with breakfast and dinner, or matching placebo, for a total duration of 26 weeks. Adherence was monitored by capsule counting at 3 and 6 months.
Laboratory
Fasting blood samples were obtained between 0800 and 1100 hours to minimize diurnal variation. The serum levels of testosterone and sex hormonebinding globulin (SHBG) were measured with a solid-phase, competitive, chemiluminescent enzyme immunoassay (IMMULITE 2000 Total Testosterone, Diagnostic Products Corporation, Los Angeles, CA, USA) at baseline and at the end of the study. Normal ranges for testosterone and SHBG are 6.3-26.8 and 13-71 nmol l À1 , respectively. The levels of free testosterone (FT) and bioavailable testosterone were calculated from total testosterone, SHBG and albumin concentrations. 14 
Sexual functioning
The 'Eleven Questions on Sexual Functioning' (ESF) questionnaire was used to assess sexual well-being at baseline and at the final visit. 15 The questionnaire consists of 11 multiple-choice questions each of 5-7 answer categories, with some questions relating to frequency of the item in the question and others to appreciation of the item in the question. Subsequently, each answer was categorized in two categories as follows: For questions about sexual fantasies, masturbation, desire of sexual contact and frequency of sexual contact, the answers were grouped as less than once a week, or once a week or more. For questions relating to difficulty with achieving and maintaining erection, achieving a climax, climaxing too quickly or climaxing too slowly and pain with sexual contact, the answers were grouped as not once, or sometimes, regularly, often or every time. For question about quality of sexual functioning, the answers were categorized into dissatisfied and neutral/satisfied. Sexual function domains were categorized in such a way that the number of participants in the smallest group was still large enough to have enough power for statistical analysis.
Possible sexual dysfunction was defined when the participant reported one or more of the following in the last month: masturbation several times a day, no or several times a day desire for sexual contact, the penis was regularly less hard or hard for a shorter time than desired with sexual contact, the participant regularly did not reach an orgasm or the orgasm was less or more quickly reached than desired, regular pain in the genitals or dissatisfaction about Testosterone supplementation on sexual function in aging men MH Emmelot-Vonk et al (X9.65 nmol l À1 )) and age (below median (60-66.5years) versus over median (66.5-80 years)).
As the percentage of missing data was very small (o6.7%), we did not use any specific strategies to handle this, and the missing data were treated as missing values in the analysis. All analyses were performed with SPSS (statistical software package, version 11.0, SPSS Inc., Chicago, IL, USA).
Results
The baseline characteristics of the participants are shown in Table 1 . The mean age of the participants was 67 ± 5 years and the mean serum testosterone concentration was 10.7±1.9 nmol l À1 . The following problems with sexual functioning were reported: 11.9% had a total lack of interest in sexual contact and 24.7% of the participants had no sexual contact in the last month, whereas 66.7% of these participants were married or unmarried but living together, 30.1% of the participants had an inability to climax and 10.5% had major problems with erectile function every time they had sexual contact. In total, 78.9% of the participants reported any sexual dysfunction. The percentage of men using PDE5 inhibitors was 1.7%. There were no major differences between the two groups at baseline.
There were 30 early withdrawals, 16 in the testosterone group and 14 in the placebo group. Of the subjects completing the study, more than 90% used at least 80% of their medication. The effects of the treatment on safety parameters and testosterone and SHBG levels have been reported earlier. 13 Briefly, there were no statistically significant differences in frequencies and types of adverse events between testosterone and placebo groups from baseline to month 6. Total testosterone was unchanged from baseline in the testosterone group and increased slightly in the placebo group; the difference between the testosterone and placebo group at month 6 was À3.2 nmol l À1 (95% confidence interval (CI): À4.2; À2.2, Po0.001). SHBG levels declined from baseline in the testosterone group but did not in the placebo group (difference À10.1 nmol l À1 , 95% CI: À11.7; À8.5, Po0.001). Moreover, the between-group difference for FT and bioavailable testosterone was statistically significant at month 6 (FT difference À0.03, 95% CI: À0.05; À0.00, P ¼ 0.04, and bioavailable testosterone difference ¼ À0.69, 95% CI: À1.24; À0.13, P ¼ 0.02, respectively.
The changes from baseline to month 6 on sexual functioning for the testosterone group and the placebo group are shown in Table 2 . There were no significant differences in sexual functioning between both groups after 6 months of intervention.
In subgroup analysis, participants were divided into two groups according to their testosterone concentration at baseline (testosterone o9.96 nmol l À1 versus testosterone X9.96 nmol l À1 ). A baseline testosterone level in the lowest tertile was associated with significantly lower scores for sexual fantasies, desire of sexual contact and frequency of sexual contact (OR (95% CI) 2.3 (1.2-4.4), 2.1 (1.1-4.0) and 2.6 (1.3-5.3), respectively). After adjustments for body mass index, blood pressure, smoking, use of alcohol, age and prior cardiovascular disease (myocardial infarction, angina, hypertension or stroke), this difference was still statistically significant for sexual fantasies, desire of sexual contact and frequency of sexual contact (Table 3) . However, after 6 months of supplementation with testosterone, there were also no significant differences in sexual functioning in the group with the lowest testosterone concentration (Table 4) .
Next, the participants were divided according to their age at baseline (o69.57 versus X69.57 years). A baseline age X69.57 years was associated with significantly lower scores for sexual fantasies and desire of sexual contact (OR (95% CI): 2.0 (1.0-3.9) and 2.6 (1.4-5.1), respectively). After adjustments for body mass index, blood pressure, smoking, use of alcohol, baseline testosterone concentration and prior cardiovascular disease, these differences were still statistically significant. (Table 5 ) After 6 months of supplementation with testosterone, there were no significant differences in sexual functioning in the group with the oldest participants ( Table 6 ). Testosterone supplementation on sexual function in aging men MH Emmelot-Vonk et al
Discussion
In this large, double-blind, placebo-controlled, randomized trial, we found that orally administered 80 mg testosterone undecanoate supplementation twice daily for 6 months to elderly men with lownormal circulating testosterone levels had no beneficial effects on sexual function. To fully appreciate these results, some issues need to be addressed. First, although the trial was of long duration relative to several earlier studies, 6 months is still a relatively short period for supplementation.
However, other studies have suggested that 6 months is long enough to find beneficial effects of testosterone supplementation on sexual function. [16] [17] [18] Moreover, this is the time period that the US Institute of Medicine of the National Academies (IOM) Committee On Assessing The Need For Clinical Trial Of Testosterone Replacement Therapy recommended to be more closely examined in a randomized trial. 19 Compliance is a common problem, especially in hormone substitution trials. However, in this study, the participants were highly motivated and compliance was good. The dropout rate was low at 13% Testosterone supplementation on sexual function in aging men MH Emmelot-Vonk et al and 207 participants for analyses make this one of the largest, double-blind, placebo-controlled, randomized trials of testosterone supplementation conducted so far. After supplementation with testosterone, there was a decrease in the SHBG concentration without an increase in the total, free and bio-available testosterone concentrations. This is in conformity with other studies using this medication. 20, 21 This finding relates to the fact that the testosterone concentrations were pre-dose levels, measured just before the intake of the following testosterone capsule. As the pharmacokinetical profile of Andriol Testocaps shows a maximum increase in testosterone after 5-6 h, this is the moment with the lowest testosterone concentrations. Owing to logistic and financial reasons, post-dose testosterone measurements were not included in the protocol of our study. Second, it is known that androgen supplementation results in a decline in SHBG concentrations, which affects the FT concentration, because most of the testosterone is bound to SHBG. The FT fraction is metabolized fast, so the total testosterone concentration decreases, especially when measured pre-dose. Third, exogenous testosterone supplementation induces a suppression of LH, resulting in a decrease in endogenous testosterone production. When measuring testosterone at a moment when levels through exogenous testosterone are low, that is pre-dose, a net decrease in testosterone can be found. Although the final testosterone level was not increased, we know from various studies that the pharmacological profile of testosterone undecanoate yields increased testosterone levels most of the 24 h. 22, 23 Moreover, at the time that this study was designed, patches and gels that provide steadier testosterone levels were not available in The Netherlands.
The total daily dose of 160 mg testosterone undecanoate orally, as used in this study, is the dose that is used in clinical practice and in other studies. 17 In our study, we have found the Effects are expressed as ORs for the treatment effect on the probability of being in the less-favorable category of the individual items of the ESF questionnaire. a Less than once a week versus once a week or more as reference. b Never versus ever as reference. c Dissatisfied versus neutral/satisfied as reference.
Testosterone supplementation on sexual function in aging men MH Emmelot-Vonk et al 27, 28 The men in this trial were selected on the basis of their androgen status and not on the basis of hypogonadal symptoms or their sexual function. More than 83% of the participants had a positive score on the ADAM questionnaire (Androgen Deficiency in Aging Males), indicating symptomatic hypogonadism. Moreover, when we compare the men in our study with those in other populationbased studies, they were similar with regard to frequency of sexual activity, but the frequency of sexual problems reported by the men in our study (80%) was more than the 33-50% reported in other studies. 1, 29 This is possibly the result of the lownormal testosterone levels of our study participants, on the basis of which they were selected.
The testosterone levels in this study population were low to low-normal. Overall 71% of the men had a testosterone level below 12.0 nmol l À1 , and are considered possibly testosterone-deficient according to conventional standards. 30 Critical testosterone levels to maintain sexual functions have been suggested to be B10.5 nmol l À1 , although they vary widely between subjects, 31 and other studies did not confirm this cutoff point. 11 Symptoms of testosterone deficiency accumulate gradually with decreasing testosterone levels, with the levels of testosterone differing between individuals and, within a subject, not all symptoms of testosterone deficiency manifesting themselves at the same blood testosterone levels. 32, 33 The testosterone levels in our study were comparable with those in other studies that reported beneficial effects of testosterone supplementation on sexual functioning. 16, 17 Moreover, the current available testosterone assays are sub-optimal for the investigation of male reproductive disorders, because of imprecision and inaccuracy of these assays. Also reference ranges will vary because of the differences that exist between methods, and this makes the suggestion of a fixed concentration less helpful.
In this study the ESF questionnaire was used to measure sexual function. This questionnaire is derived from the Questionnaire for screening Sexual Dysfunctions (QSD). 15 This is a validated questionnaire, which is used for clinical and scientific purposes in the Netherlands. 34, 35 The most often used questionnaire internationally is the International Index of Erectile Function (IIEF). 36 This 15-item, self-assessed questionnaire is developed for the assessment of erectile function and it is not intended for use as a measure for overall sexual function. In this questionnaire, five factors or response domains are identified: erectile function, orgasmic function, sexual desire, intercourse satisfaction and overall satisfaction. The ESF used in our study is comparable with the IEFF: 7 of the 11 questions are similar to questions of the IEFF and the questions of the ESF cover 4 of the 5 domains described in the IEFF. Moreover, the ESF is intended for use as a measure of overall sexual function and that is the reason why we have chosen it for this questionnaire.
The results of our study are consistent with those of some others, 37, 38 but other studies have shown positive results of supplementation of testosterone on sexual function. 16, 17 A meta-analysis has shown that testosterone use may be associated with small improvements in erectile function and moderate improvement in libido in elderly men. 10, 11 However, unexplained inconsistent results across trials, wide confidence intervals and possible reporting bias weaken these inferences. This meta-analysis has also shown that sexual function is more likely to improve with testosterone supplementation in men with severe degrees of hypogonadism. 10, 11 In our study, we found a negative association between baseline testosterone concentration and sexual fantasies, desire of sexual contact and frequency of sexual contact, but no association between baseline testosterone concentration and erectile functioning as in earlier studies. 6, 39 Despite this difference, after 6 months of supplementation with testosterone, there was no improvement of these items of sexual function in the testosterone group compared with those in the placebo group in the lowest testosterone concentration in this study. Also, we found an inverse association between higher age and sexual fantasies and desire of sexual contact. We know from earlier studies that aging is accompanied by an increase in sexual problems. 1 Nevertheless, there was no effect of testosterone supplementation on sexual functioning in the testosterone group compared with that in the placebo group in the oldest participants of this study.
Some studies that did provide evidence for a beneficial effect of testosterone supplementation on sexual functioning were conducted in younger men, and this might be explained by the fact that they do have less co-morbid illnesses that interfere with sexual functioning. 24, 40 Owing to the relatively high age of the participants in our study, it is likely that there were more causes for erectile dysfunction than the low-normal testosterone concentrations alone, such as neurological causes, cardiovascular diseases (arterial insufficiency, venous leak) and depression. Testosterone replacement therapy alone will not correct these problems.
In conclusion, the findings of this large randomized trial do not support the presence of an effect of testosterone supplementation on sexual function in men with low-normal testosterone levels during a period of 6 months.
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